Sfoglia per Autore
Adjuvant treatment of early male breast cancer
2020-01-01 C. Corti, E. Crimini, C. Criscitiello, D. Trapani, G. Curigliano
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions
2021-01-01 M. Repetto, E. Crimini, F. Giugliano, S. Morganti, C. Belli, G. Curigliano
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials
2021-01-01 P. Trillo Aliaga, D. Trapani, J.L. Sandoval, E. Crimini, G. Antonarelli, G. Vivanet, S. Morganti, C. Corti, P. Tarantino, A. Friedlaender, C. Belli, I. Minchella, M. Locatelli, A. Esposito, C. Criscitiello, G. Curigliano
Clinical development and current role of margetuximab for the treatment of breast cancer
2021-01-01 P. Tarantino, J. Uliano, S. Morganti, F. Giugliano, E. Crimini, G. Curigliano
Systemic Treatment of Ductal Carcinoma In Situ of the Breast
2021-01-01 E. Crimini, C. Corti, M. Repetto, F. Giugliano, G. Antonarelli, P. Tarantino, P. Zagami, S. Morganti, E. Nicolo, J. Uliano, G. Curigliano
First line treatment of BRAF mutated advanced melanoma: Does one size fit all?
2021-01-01 F. Giugliano, E. Crimini, P. Tarantino, P. Zagami, J. Uliano, C. Corti, D. Trapani, G. Curigliano, P.A. Ascierto
Margetuximab for the treatment of HER2-positive metastatic breast cancer
2021-02-01 P. Tarantino, S. Morganti, J. Uliano, F. Giugliano, E. Crimini, G. Curigliano
Benefit of adjuvant chemotherapy in patients with lobular breast cancer : A systematic review of the literature and metanalysis
2021-04-09 D. Trapani, S. Gandini, C. Corti, E. Crimini, F. Bellerba, I. Minchella, C. Criscitiello, P. Tarantino, G. Curigliano
SARS-CoV-2 vaccines for cancer patients: a call to action
2021-05-01 C. Corti, E. Crimini, P. Tarantino, G. Pravettoni, A.M.M. Eggermont, S. Delaloge, G. Curigliano
Precision medicine in breast cancer : From clinical trials to clinical practice
2021-05-12 E. Crimini, M. Repetto, P. Aftimos, A. Botticelli, P. Marchetti, G. Curigliano
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
2022-01-01 K. Venetis, E. Crimini, E. Sajjadi, C. Corti, E. Guerini-Rocco, G. Viale, G. Curigliano, C. Criscitiello, N. Fusco
Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?
2022-01-01 S. Morganti, A. Marra, E. Crimini, P. D'Amico, P. Zagami, G. Curigliano
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile